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Purpose of the study
The presentation will report long-term (>4-year) data on
safety and efficacy of antiretroviral regimes including NVP
as a component of their antiretroviral therapy in five cent-
ers' databases, and included in a retrospective cohort
study.
Methods
Data collected included lipid and liver function tests, viral
load and CD4 cell counts at baseline, 2-year and >4-year
timepoints. HCV co-infection, adverse events, and reason
for using NVP were also recorded.
Summary of results
229 patients (pts) were included. Mean age was 37 years.
Most pts (54%) were former intravenous drug users. 135
individuals were co-infected with HCV. Median time on
NVP was 72.6 months. The main reasons to use NVP were:
second or third-line therapy (40%), simplification (30%),
first-line therapy (19%), and efavirenz intolerance (10%).
Combinations of nucleosides most widely used were:
ABC+3TC (25%), AZT+3TC (23%) and TDF+3TC (14%).
HDL-cholesterol and GGT increased from baseline to >4-
year timepoint (48 mg/dl to 62 mg/dl and 58 U/l to 145
U/l, respectively). LDL-cholesterol, triglycerides and alka-
line phosphatase showed decreasing values at follow-up
(135 mg/dl to 109 mg/dl, 216 to 153 mg/dl, and 177 to
92, respectively). Total cholesterol and liver function tests
had no significant changes. CD4 cell counts increased
from 439/mm3 at baseline to 628/mm3 at the last availa-
ble visit. 172 out of 184 pts who remained on NVP-based
therapy at last visit maintained viral load values below
limit of detection. NVP was stopped or withdrawn in 43
patients due to virological failure (13 pts), toxicity (five
pts), virological resistance (four pts), therapy interruption
(three pts), death (two pts), dyslipidemia (one pt), sim-
plification (one pt) or unknown reasons (14 pts). Adverse
events were reported in 40 patients but none was directly
attributed to NVP. The reported follow-up pattern of lab-
oratory tests was also found in the subset of HCV co-
infected patients by comparing men and women and
stratifying patients with a CD4 cell count cut-off value of
250/mm3.
Conclusion
Results suggest that NVP-based antiretroviral therapy
(either first-line, simplification, or second-line) not only
provides stable immunological and virological efficacy for
over 4 years, as well as a favourable safety profile with few
adverse events leading to discontinuation, but also
increases HDL-cholesterol, which may have a protective
impact on cardiovascular risk. The same safety profile was
found in the subpopulation of HCV co-infected patients
and individuals with CD4 cell counts above 250/mm3.
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